Biliary cirrhosis is an autoimmune disease of the kidney that results in the damage of small bile ducts of the liver, caused due to build-up of bile within the liver. The pressure formed by the accumulation of bile leads to severe liver cell damage. Due to weak immune systems, bile ducts are damaged accompanied with higher levels of bile in the liver, finally resulting into cirrhosis.
Browse the full Biliary Cirrhosis Market Report with TOC @
The various symptoms associated with biliary cirrhosis are as follows:
- Fatigue
- Itchiness of the skin
- Dry mouth and eyes
- Abdominal pain
- Yellowing of skin
- Vaginal dryness
The diagnosis of biliary cirrhosis is done through various liver function tests such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, bilirubin, complete blood count (CBC) and cholesterol level tests. Other imaging tests include ultrasound, magnetic resonance imaging (MRI), and computerized tomography.
Based on treatment, the biliary cirrhosis market can be segmented as follows:
- Ursodeoxycholic acid (UDCA): UDCA is a bile acid that helps in smooth movement of bile in the liver. UDCA does not primarily cure biliary cirrhosis but is considered the first line of therapy as the treatment reduces the need for a liver transplant. Side-effects of this treatment include weight gain, vomiting, nausea and hair loss.
- Corticosteroids: Corticosteroids contain steroids that suppress an individual’s immune system in order to reduce inflammation. For instance, prednisolone.
- Liver transplant: In case of total liver failure, liver transplant may be performed. Administration of immunosuppressants is necessary after liver transplantation as the immune system may reject the donated liver.
- Treatment for itchiness: Treatment of itchiness associated with biliary cirrhosis is usually treated with a drug, colestyramine.
Geographically, the biliary cirrhosis market is segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Europe holds the leading position in the market followed by North America. The factors which are driving the growth of biliary cirrhosis market are rapidly increasing women population with biliary cirrhosis, and increasing demand for sophisticated advanced testing tools and diagnostics. Furthermore, increasing sedentary habits such as smoking, drinking and use of tobacco are also considered to increase the risk of biliary cirrhosis among the population. According to a study, the prevalence of biliary cirrhosis has been estimated as 12.9 per 100,000 population with 90% of the cases occurring in women. Asia Pacific is one of the fastest growing regions for the growth of biliary cirrhosis market. The beneficial factors that will boost the growth of the biliary cirrhosis treatment market in Asia Pacific are increasing population base, rise in the number of weakened immune systems especially among the female geriatric population and growing awareness of people in developing nations about the available treatment options. Moreover, other factors such as tax benefits, easy market penetration and favorable reimbursement policies would also augment the growth of the market in the next few years.
At present, various pharmaceutical companies are coming up with novel and advanced therapeutics for the development of biliary cirrhosis market. Some of the top players operating in biliary cirrhosis market are Pfizer, Inc., Teva Pharmaceuticals USA, Inc., GlaxoSmithKline plc, Johnson & Johnson, Intercept Pharmaceuticals, Inc, Lumena Pharmaceuticals, Inc. and many others.
Enquiry before Buying @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3352
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
